论文部分内容阅读
目的通过爱普列特和保列治治疗后患者血清性激素水平变化的研究,为临床提供用药参考。方法2005年在我院就诊的门诊前列腺增生患者88例。分别于治疗开始前和治疗后12周采血测血清性激素(LH、T、f-T、DHT、E2)。结果爱普列特组在治疗12周后E2上升,DHT下降,前后比较有显著性差异(P<0.05)。保列治组在治疗12周后LH上升,T上升,DHT下降,均有显著性差异(P<0.05)。两组治疗后性激素变化比较在LH和T的水平上有统计学意义(P<0.05)。结论爱普列特和保列治是两种不同的Ⅱ型5α-还原酶抑制剂,治疗后对血清性激素的影响也不同。
Objective To study the changes of serum sex hormone levels in patients treated with Epsilon and Proliferation and to provide reference for the clinical use. Methods In 2005, 88 outpatients with benign prostatic hyperplasia were treated in our hospital. Serum sex hormones (LH, T, f-T, DHT, E2) were collected before treatment and 12 weeks after treatment. Results E2 was increased and DHT decreased after 12 weeks of treatment in the adeptrex group. There was a significant difference between before and after treatment (P <0.05). Proliferation group after 12 weeks of treatment, LH increased, T increased, decreased DHT, were significantly different (P <0.05). The changes of sex hormones after treatment in both groups were statistically significant at LH and T levels (P <0.05). Conclusions Epristeride and Proluvula are two different type II 5-AR reductase inhibitors that have different effects on serum sex hormones after treatment.